Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03716258 · ClinicalTrials.gov registry record
Characterizing Biomarkers of Early Parkinson's Disease Progression (TREG)
A clinical trial, sponsored by Oregon Health and Science University.
- Terminated
- Registry status
- 16
- Enrollment target
NCT03716258: Clinical Trial study, sponsored by Oregon Health and Science University.
NCT03716258 is a clinical trial that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03716258 was terminated before completion, sponsored by Oregon Health and Science University.
- TERMINATED
- Registry status
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to look at a blood marker of inflammation in early untreated Parkinson's disease.
Primary Outcome
Change in peripheral blood Treg number (expressed as percentage of total helper T cells) over a 12 month time period in PD patients
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2021-05-01 |
Why NCT03716258 stopped before completion
NCT03716258 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03716258 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03716258 about?
NCT03716258 is a clinical study titled "Characterizing Biomarkers of Early Parkinson's Disease Progression (TREG)". The purpose of this study is to look at a blood marker of inflammation in early untreated Parkinson's disease.
What is the current status of trial NCT03716258?
This trial is currently terminated. The enrollment target is 16 participants. The study started on 2019-01-01. Estimated completion is 2021-05-01.
Who is sponsoring clinical trial NCT03716258?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI